and in vitro antitumoral activity of novel
O,O’-di-2-alkyl-(S,S)-ethylenediamine-N,N’-di-2-propanoate ligands and
corresponding platinum(II/IV) complexes.
stem cells in patients with chronic myelogenous leukaemia or
bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic
outcome of complete cytogenetic responders after imatinib 400 mg in
late chronic phase, philadelphia-positive chronic myeloid leukemia: the
GIMEMA Working Party on CML.
responses in chronic myeloid leukemia patients maintained with lower
doses of imatinib mesylate after achieving molecular remission.
myeloid leukemia developing during imatinib mesylate therapy for
chronic myeloid leukemia in the absence of new cytogenetic